AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real Time Price. Currency in SEK
712.00
-3.20 (-0.45%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close715.20
Open715.00
Bid711.40 x 0
Ask711.80 x 0
Day's Range705.70 - 715.20
52 Week Range461.30 - 722.70
Volume325,927
Avg. Volume313,213
Market Cap892.905B
Beta0.82
PE Ratio (TTM)321.59
EPS (TTM)2.21
Earnings DateN/A
Forward Dividend & Yield22.50 (3.70%)
Ex-Dividend Date2018-02-15
1y Target Est92.22
  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks4 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Reuters6 days ago

    AstraZeneca settles Texas drug lawsuits for $110 mln

    Drugmaker AstraZeneca has agreed to pay $110 million to settle two lawsuits brought by the state of Texas claiming that it fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol. The largest settlement, totalling $90 million, resolves allegations the drugmaker encouraged doctors to use Seroquel for unapproved uses. A second settlement for $20 million covers allegations it misrepresented the benefits of Crestor.

  • Bloomberg7 days ago

    AstraZeneca to Pay $110 Million to Settle Texas Drug Suits

    AstraZeneca Plc agreed to pay $110 million to settle a Texas claim alleging that the company cheated the state’s Medicaid program by fraudulently marketing two medications, according to the state’s attorney general office. Texas claimed the drugmaker had targeted the state’s Medicaid program by urging doctors to prescribe its antipsychotic drug Seroquel for unapproved treatments, and that it had misrepresented Crestor, a cholesterol fighter, as superior to other statins. Texas claimed AstraZeneca promoted Seroquel to Medicaid providers who primarily treated children and adolescents when it wasn’t approved as safe or effective for that population.

  • To Get the Latest Drugs, Head to China
    Bloomberg12 days ago

    To Get the Latest Drugs, Head to China

    It’s been less than a year since Beijing cut back red tape on drug approvals and already Chinese patients can expect to get some breakthrough medicines before Americans. Britain’s AstraZeneca Plc will bring its newest anemia treatment to pharmacies in Shanghai and Beijing about a year before it’s available in U.S. cities. “Twenty years from now, China’s going to have a market that’s comparable, or possibly bigger, than the U.S.,” said Daniel Mahony, a health-care fund manager with Polar Capital LLP in London.

  • Benzinga18 days ago

    Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...

  • Reuters18 days ago

    AstraZeneca's key lung cancer drug wins European panel thumbs-up

    EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body. While final approvals are up to the European Commission, it generally follows the CHMP's recommendation and endorses them within a couple of months.

  • Reuters18 days ago

    AstraZeneca's key lung cancer drug wins European panel thumbs-up

    AstraZeneca's cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets. EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body. While final approvals are up to the European Commission, it generally follows the CHMP's recommendation and endorses them within a couple of months.

  • AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
    Zacks19 days ago

    AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

    AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

  • New drugs shine as AstraZeneca treads path back to growth
    Reuters19 days ago

    New drugs shine as AstraZeneca treads path back to growth

    AstraZeneca's new drugs performed strongly in the second quarter, offering a glimpse of better times ahead as the company struggles with falling sales of cholesterol fighter Crestor due to generic competition. Cancer medicines were a highlight, including demand for Imfinzi, following U.S. approval of the immunotherapy in early lung cancer, and Chief Executive Pascal Soriot said the company remained on track for a return to product sales growth in 2018. China was once again a bright spot, as AstraZeneca continues to outperform competitors in the world’s second biggest drugs market, where it is using digital apps and other healthcare technology to help sell its medicines.

  • Reuters19 days ago

    AstraZeneca joins U.S. drug price freeze for rest of 2018

    AstraZeneca has joined other drugmakers in freezing prices in the United States for the rest of 2018, following criticism by U.S. President Donald Trump over the cost of medicine. Chief Executive Pascal Soriot said on Thursday the British company had no plans for second-half increases, matching similar commitments from Pfizer, Novartis, Roche and Merck. In the first half, AstraZeneca raised U.S. list prices by a "modest" 1 to 3 percent, while net prices after rebates are actually falling, he said.

  • Associated Press19 days ago

    Astrazeneca: 2Q Earnings Snapshot

    On a per-share basis, the Cambridge, Britain-based company said it had profit of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 69 cents per share. The results topped ...

  • Reuters19 days ago

    New drugs shine as AstraZeneca battles through generic losses

    AstraZeneca's new drugs performed strongly in the second quarter, offering a glimpse of better times ahead as the company struggles with falling sales of cholesterol fighter Crestor due to generic competition. Cancer medicines were a highlight, including good demand for Imfinzi, following U.S. approval of the immunotherapy in early lung cancer, and Chief Executive Pascal Soriot said the company remained on track for a return to product sales growth in 2018. China was also once again a bright spot, as AstraZeneca continues to outperform competitors in the world’s second biggest drugs market, and the UK drugmaker's shares rose 2 percent in early trade on Thursday as investors cheered the growing evidence of recovery.

  • Associated Press19 days ago

    AstraZeneca says 2nd-quarter earnings dropped 27 percent

    LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings dropped 27 percent as it shifted away from dependence on its former blockbuster drugs and toward new cancer drugs.

  • AstraZeneca’s New Medicines Buoy Second-Quarter Results
    Bloomberg19 days ago

    AstraZeneca’s New Medicines Buoy Second-Quarter Results

    AstraZeneca Plc’s newer products are giving the company a lift, helping profit beat estimates in the second quarter. Adjusted earnings were 69 cents a share, the Cambridge, England-based company said in a statement Thursday, compared with the 61 cents analysts had forecast. Astra is trimming costs and pushing a series of new products including Lynparza for breast cancer and Imfinzi for lung cancer that are intended to sustain earnings for years to come.

  • Benzinga20 days ago

    A Preview Of AstraZeneca's Q2 Earnings

    On Thursday, AstraZeneca (NYSE: AZN ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue AstraZeneca EPS is ...

  • Benzinga20 days ago

    Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 23) AstraZeneca plc (ADR) (NYSE: AZN )(Sold rights to heart drugs ...

  • AstraZeneca Sells Atacand's European Rights to Cheplapharm
    Zacks21 days ago

    AstraZeneca Sells Atacand's European Rights to Cheplapharm

    AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

  • What Analysts Think about AstraZeneca and Peers in July
    Market Realist25 days ago

    What Analysts Think about AstraZeneca and Peers in July

    AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017, a decrease of 1.56%. AstraZeneca is expected to report net income per share of $0.04 in Q2 2018 as compared with $0.19 in Q2 2017. Four of the total six analysts covering AstraZeneca in July 2018 have given it a “buy” or higher rating.

  • What to Expect from AstraZeneca’s Second-Quarter Earnings
    Market Realist25 days ago

    What to Expect from AstraZeneca’s Second-Quarter Earnings

    AstraZeneca (AZN), the maker of key products like Lynparza, Tagrisso, Imfinzi, Brilinta, and Farxiga, is expected to report Q2 2018 earnings on July 26. AstraZeneca’s revenues are expected to increase 0.77% from $5.05 billion in Q2 2017 to $5.09 billion in Q2 2018. In fiscal 2017, AstraZeneca generated $22.46 billion in revenues.

  • Reuters25 days ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters25 days ago

    EU drug regulators step up work to prepare for 'no deal' Brexit

    Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit. Although the UK's exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

  • Reuters27 days ago

    AstraZeneca to stockpile drugs as Brexit 'safety net'

    AstraZeneca (AZN.L) is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal. The move affects drugs made in Britain that could be exported to Europe and supplies in the European Union that may be headed the other way. A company spokesman said on Wednesday that AstraZeneca currently held several months of supplies of such medicines and this was being increased for products on both sides of the Channel.

  • AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer
    Market Realistlast month

    AstraZeneca Reports Promising Data for Lynparza in Ovarian Cancer

    On June 27, AstraZeneca (AZN) and Merck (MRK) reported positive data for their Phase 3 Lynparza trial, SOLO-1, a randomized, double-blind, placebo-controlled trial for ovarian cancer. The drug met the primary endpoint of progression-free survival in women with BRCA1-mutated advanced ovarian cancer. Lynparza is the only PARP2 inhibitor to show significant activity in a first-line maintenance setting. Based on this data, the two companies plan to initiate discussions with authorities for regulatory submissions.